Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series
Clinical outcomes from three heavily pretreated patients with metastatic HER2+/HR+ MBC demonstrated that margetuximab plus chemotherapy resulted in real-world PFS comparable to that reported in the controlled pivotal clinical trial and support use of this targeted therapy option in appropriately identified patients.
Authors
- Reshma Mahtani (ORCID: https://orcid.org/0000-0002-7711-8627)
- Iuliia Kovalenko (ORCID: https://orcid.org/0000-0003-4821-2195)
- Kristen L. Phiel
- Natasha Harpalani
- Fengting Yan
Institutions
- Baptist Hospital of Miami (US)
- Memorial Sloan Kettering Cancer Center (US)
- Swedish Medical Center (US)
- Baptist Health South Florida (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-08-16
- DOI
- https://doi.org/10.3389/fonc.2024.1419246
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- MacroGenics